Impact on States of the Medicare Drug Benefit: Information for State Administrators
As administrators work to integrate Medicaid and state prescription assistance programs with the new drug benefit established by Part D of the Medicare Modernization Act, there will be significant savings opportunities as well as significant costs. The decisions states make must not only reflect budget considerations, but must also recognize the lead role that states have in providing a safety net to the poorest, frailest, and most vulnerable of our citizens. This issue brief identifies key decision points and factors that must be taken into consideration as states prepare for the January 1, 2006, implementation of the new Medicare drug benefit.
E.V.I.dently May 2013
Message From NPCThe Role of Pharmaceuticals in Health Insurance ExchangesOne of the most pressing issues in the implementation of the Affordable Care...
The Role of Pharmaceuticals in Health Insurance Exchanges
As part of the implementation of the Affordable Care Act, a series of state health insurance exchanges are being established across the United States...A Look at Rx Coverage and Cost in the New Health Insurance Exchanges
National Pharmaceutical Chief Science Officer Dr. Robert Dubois will lead a panel discussion, "Capturing the Value of Pharmaceuticals--A Look at Rx...NPC Welcomes Dr. Bryan Luce as PCORI Chief Science Officer
The National Pharmaceutical Council today welcomed the news that the Patient-Centered Outcomes Research Institute (PCORI) has appointed its first...
Study Quantifies Impact of Pharmaceuticals on Enhanced Productivity
(WASHINGTON, DC, August 1, 2012)–The costs to employers of chronic health conditions on employee productivity are well documented, but few studies...Pharmaceuticals Play Key Role in Achieving ACO Quality, Cost Goals
WASHINGTON, DC, July 18, 2012–As health care providers set up accountable care organizations (ACOs) and other value-based care programs,...NPC Conference to Address Questions on Ability to Share Health Research Findings Health
(Washington, DC, February 6, 2012)--To examine key issues around asymmetries, or inequalities, in communicating health information coming from the...National Pharmaceutical Council Selects Five Research Projects for Funding
Washington, DC (January 30, 2012) – The National Pharmaceutical Council (NPC) today announced that it has selected five projects related to...
Living Up to Its Name? The Role of Patient-Centered Research
Anyone who has ever received bad news from his or her health care provider or held a loved one’s hand when a diagnosis was delivered can understand...High Stakes for Setting Research Standards
What is the cost of poorly designed research? In the comparative effectiveness arena, faulty studies could mean that consumers may make important...Framework Helps ACOs Leverage Pharmaceuticals to Realize Quality, Cost Goals
Medications are more than an item on the balance sheet for health care providers. Pharmaceuticals offer a route to manage costs while achieving...Asymmetry in the Ability to Communicate CER Findings: Ethics and Issues for Informed Decision Making
The number of voices in the comparative effectiveness research (CER) conversation is continuing to grow, but not all stakeholders have the same...
How Do Payers Consider Individual Treatment Effects?
Dr. Robert Epstein, former chief medical officer and senior vice president of medical affairs at Medco Health, explains that heterogeneity, or...AEI's Gottlieb on Ability to Communicate CER Findings
American Enterprise Institute's Dr. Scott Gottlieb discusses legal and regulatory challenges facing various health care stakeholders in their...CER, FDA and the Free Speech Challenge
Dr. Tevi Troy, former Deputy Secretary of the U.S. Department of Health and Human Services, explains some of the Food and Drug Administration's...The Challenges of Finding, Using Accurate Health Care & CER Information
Dr. Art Caplan, Director of the Center for Bioethics at the University of Pennsylvania, explains that it can be challenging for patients to find...The Role of Pharmaceuticals in Health Insurance Exchanges
As part of the implementation of the Affordable Care Act, a series of state health insurance exchanges are being established across the United States...A Look at Rx Coverage and Cost in the New Health Insurance Exchanges
National Pharmaceutical Chief Science Officer Dr. Robert Dubois will lead a panel discussion, "Capturing the Value of Pharmaceuticals--A Look at Rx...NPC Welcomes Dr. Bryan Luce as PCORI Chief Science Officer
The National Pharmaceutical Council today welcomed the news that the Patient-Centered Outcomes Research Institute (PCORI) has appointed its first...Evidence, Coverage and Incentives: Challenges in Personalized Medicine
Personalized medicine is greatly changing the way medicine is practiced, as well as how drugs and biologics are developed. Today patients are...Research
Pharmaceutical Benefits Under State Medical Assistance Programs, 2007
This report provides a compilation of data under state medical or state public medical assistance...
Pharmaceutical Benefits Under State Medical Assistance Programs, 2005
This report, part of the Pharmaceutical Benefits Und
Pharmaceutical Benefits Under State Medical Assistance Programs, 2004
This report, part of the Pharmaceutical Benefits Und
- 1 of 43
- >
Commentary & Testimony
Living Up to Its Name? The Role of Patient-Centered Research
High Stakes for Setting Research Standards
Framework Helps ACOs Leverage Pharmaceuticals to Realize Quality, Cost Goals
Asymmetry in the Ability to Communicate CER Findings: Ethics and Issues for Informed Decision Making
CER Done Right: Why It Matters